Is It Time to Use Modeling of Cellular Transporter Homeostasis to Inform Drug-Drug Interaction Studies: Theoretical Considerations
- 25 August 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 23 (5), 1-14
- https://doi.org/10.1208/s12248-021-00635-4
Abstract
Mathematical modeling has been an important tool in pharmaceutical research for 50 + years and there is increased emphasis over the last decade on using modeling to improve the efficiency and effectiveness of drug development. In an earlier commentary, we applied a multiscale model linking 6 scales (whole body, tumor, vasculature, cell, spatial location, time), together with literature data on nanoparticle and tumor properties, to demonstrate the effects of nanoparticle particles on systemic disposition. The current commentary used a 4-scale model (cell membrane, intracellular organelles, spatial location, time) together with literature data on the intracellular processing of membrane receptors and transporters to demonstrate disruption of transporter homeostasis can lead to drug-drug interaction (DDI) between victim drug (VD) and perpetrator drug (PD), including changes in the area-under-concentration–time-curve of VD in cells that are considered significant by the US Food and Drug Administration (FDA). The model comprised 3 computational components: (a) intracellular transporter homeostasis, (b) pharmacokinetics of extracellular and intracellular VD/PD concentrations, and (c) pharmacodynamics of PD-induced stimulation or inhibition of an intracellular kinetic process. Model-based simulations showed that (a) among the five major endocytic processes, perturbation of transporter internalization or recycling led to the highest incidence and most extensive DDI, with minor DDI for perturbing transporter synthesis and early-to-late endosome and no DDI for perturbing transporter degradation and (b) three experimental conditions (spatial transporter distribution in cells, VD/PD co-incubation time, extracellular PD concentrations) were determinants of DDI detection. We propose modeling is a useful tool for hypothesis generation and for designing experiments to identify potential DDI; its application further aligns with the model-informed drug development paradigm advocated by FDA. Graphical abstractKeywords
This publication has 85 references indexed in Scilit:
- N-glycosylation Dictates Proper Processing of Organic Anion Transporting Polypeptide 1B1PLOS ONE, 2012
- Endosome maturationThe EMBO Journal, 2011
- In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug InteractionsPharmaceutical Research, 2011
- Protein Kinase C-dependent Ubiquitination and Clathrin-mediated Endocytosis of the Cationic Amino Acid Transporter CAT-1Online Journal of Public Health Informatics, 2011
- Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2British Journal of Pharmacology, 2011
- How is the balance between protein synthesis and degradation achieved?Theoretical Biology and Medical Modelling, 2010
- Rapid Modulation of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1, SLCO2B1) Function by Protein Kinase C-mediated Internalization*Online Journal of Public Health Informatics, 2010
- Pathways and mechanisms of endocytic recyclingNature Reviews Molecular Cell Biology, 2009
- Organic Anion Transporter OAT1 Undergoes Constitutive and Protein Kinase C-regulated Trafficking through a Dynamin- and Clathrin-dependent PathwayOnline Journal of Public Health Informatics, 2008
- Imaging and imagination: understanding the endo-lysosomal systemHistochemistry and Cell Biology, 2008